dc.creator | Lakić, Dragana | |
dc.creator | Tasić, Ljiljana | |
dc.creator | Kos, Mitja | |
dc.creator | Odalović, Marina | |
dc.creator | Tadić, Ivana | |
dc.date.accessioned | 2019-09-02T11:28:33Z | |
dc.date.available | 2019-09-02T11:28:33Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 1098-3015 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/1684 | |
dc.description.abstract | OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’
of mortality, morbidity and economic losses. The aim of this study was to estimate
the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS:
For the purpose of the study CVD was defined by the International Classification of
Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis-
ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence,
top-down method was used to quantify the annual cardiovascular costs. Produc-
tivity losses were estimated using the human capital approach and the friction cost
method. Data were collected from Serbian Health Insurance Fund and National
Public Health Institute “Batut”. A discount rate of 5% was used to convert all future
lifetime earnings into the present value. RESULTS: The total direct costs of CVD in
2009 were € 400 million. The majority of total costs (€ 514.3 million) were for:
medication (29.94%), hospital days (28.97%) and hospital inpatient care — surgical
and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac-
counted for 22.15% of total costs. The results showed that more than half a million
working days were lost due to incapacity resulting from CVDs. The results were
robust to a change in 20% of volume or the unit price of all direct and indirect cost
and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre-
sented approximately 1.8% of the Serbian gross domestic product. The results of
study would be valuable to health policy makers to bridge the gap between in-
vested resources and needs, in order to improve cardiovascular disease outcomes. | |
dc.publisher | Elsevier Inc. | |
dc.rights | openAccess | |
dc.source | Value in Health | |
dc.title | Cost of cardiovascular diseases in Serbia | en |
dc.type | conferenceObject | |
dc.rights.license | ARR | |
dcterms.abstract | Лакић, Драгана; Тадић, Ивана; Одаловић, Марина; Тасић, Љиљана; Кос, Митја; | |
dc.citation.volume | 15 | |
dc.citation.issue | 7 | |
dc.citation.spage | A367 | |
dc.citation.epage | A367 | |
dc.citation.other | 15(7): - | |
dc.citation.rank | M21 | |
dc.description.other | Research poster presentations – session II | |
dc.description.other | Disease-specific studies: Cardiovascular disorders - cost studies | |
dc.description.other | ISPOR 15th Annual European Congress and ISPOR 5th Asia-Pacific Conference | |
dc.identifier.wos | 000312411100480 | |
dc.identifier.doi | 10.1016/j.jval.2012.08.974 | |
dc.identifier.fulltext | http://farfar.pharmacy.bg.ac.rs/bitstream/id/10193/Cost_of_cardiovascular_pub_2012.pdf | |
dc.type.version | publishedVersion | |